Medical Devices Growth Investors & VC Firms
523 firms in this list, with a median first check of $1.1M. 130 of them lead rounds. Generated from verified public data and updated continuously.
Investinor
TrondheimPre-Seed–Growth
44 people
Avista
New YorkGrowth
40 people
AME Cloud Ventures
Palo AltoSeed–Late Stage$1M – $10M
11 people
Vensana Capital
MinneapolisSeries A–Growth
44 people
Ireland Strategic Investment Fund
DublinSeed–Late Stage
Sandbox Industries
ChicagoSeed–Growth
35 people
Heritage Group
NashvilleSeed–Growth$15M
41 people
Indaco Venture Partners
MilanSeed–Growth
28 people
aMoon
Ra'ananaSeed–Late Stage
33 people
Northern Gritstone
ManchesterSeed–Growth
41 people
Blue Venture Funds
ChicagoSeed–Late Stage$1M – $20M
28 people
Delta-v Capital
DenverGrowth$2M – $10M
30 people
Clarendon Fund Managers Ltd.
BelfastPre-Seed–Growth$63K – $3.8M
13 people
Northlane Capital Partners
BethesdaGrowth$25M – $150M
29 people
SHS Capital
TübingenGrowth$10M – $50M
43 people
Blue Sea Capital
West Palm BeachGrowth
38 people
Kaiser Permanente Ventures
San FranciscoSeed–Growth$2M – $5M
14 people
RoundTable Healthcare Partners
Lake ForestGrowth
36 people
OSAKA University Venture Capital
OsakaPre-Seed–Growth
20 people
Avoro Capital Advisors
New YorkSeries A–Late Stage
22 people
Novartis Venture Fund
BaselSeed–Growth$5M – $25M
22 people
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$200K – $5M
25 people
JAZZ Venture Partners
San FranciscoSeed–Growth$100K – $20M
16 people
Keio Innovation Initiative
TokyoSeed–Growth
22 people
Related lists
Growth Investors & VC Firms (4301)Growth Investors & VC Firms in North America (2155)Growth Investors & VC Firms in United States (1870)Medical Devices Investors & VC Firms (1659)Growth Investors & VC Firms in Europe (1648)Growth Investors & VC Firms in Global (1397)Medical Devices Seed Investors & VC Firms (1321)Healthtech Growth Investors & VC Firms (1282)Growth Investors & VC Firms in Asia-Pacific (1264)Enterprise Software Growth Investors & VC Firms (1211)
Data sourced from public filings and firms' own websites — see our methodology.









































































































